Aimei Health Technology Co., Ltd

Public shareholders tracking the redemption calendar must now align their exercise windows to the revised July 6, 2026 liquidation trigger, preserving their statutory right to redeem shares at the prevailing trust value before that date. By routing the extension funding through a sponsor-led promissory note that contractually surrenders recourse to the trust account, the Company structurally protects existing public trust balances from external creditor claims while securing additional operational runway. The explicit inclusion of United Hydrogen Group Inc. as a co-payee on the extension debt provides verified, contract-level evidence of deal negotiation progression, materially reducing information asymmetry regarding target selection. The predetermined $10.00 conversion floor locks in the exact post-combination unit economics for participating sponsors, establishing clear dilution parameters ahead of a definitive proxy statement or merger agreement.

The notice establishes a clear delisting pathway should the Company miss its filing window or fail to satisfy Nasdaq’s conditions. For a SPAC awaiting a merger closure, an administrative lag and potential exchange removal risk can pressure shareholder sentiment around redemption timing. Management stated it expects to regain compliance and reiterated its strategic focus on healthcare innovation. Because the filing provides no updated financials, investors cannot track interim trust balance consumption or sponsorship funding milestones during the 60-day or 180-day cure periods, leaving standard redemption deadline mechanics unchanged but operationally opaque.

Because the registrant advanced the Termination Date to June 6, 2026, public shareholders retain an additional thirty-day redemption window prior to the next extension cycle. The $34,330.96 deposit mechanically increases the trust balance allocated to satisfy potential redemptions. The filing reveals that the Sponsor and United Hydrogen Group Inc. are funding the extension period through a deferred credit instrument rather than immediate equity; the $34,330.96 obligation carries zero interest and will either convert to equity post-merger or mature at the closing date. As the Company identifies this as the eighteenth allowable extension, it indicates the SPAC is operating near the statutory extension ceiling, extending execution uncertainty. Under Sections 8 and 12 of the Promissory Note, the Payees expressly waive all claims against the trust account, legally ring-fencing those deposited funds exclusively for public shareholders in the event of liquidation. The submission contains no disclosures regarding projected revenues, target customer bases, market sizing, proprietary technology, strategic partnerships, pending litigation, or executive compensation changes.

The scale of redemptions indicates strong capital flight, directly reducing the pool available for either a completed merger or pro-rata liquidation distributions. The delayed timeline and ongoing regulatory hurdles shift market and liquidity risk well into 2026, while the disclosed internal control deficiency introduces potential audit and restatement risks that could further complicate the transaction or trigger a liquidation event.

Delisting risk directly threatens the tradability of ordinary shares, rights exchangeable into one-fifth of one ordinary share, and units comprising those components, which carry a par value of $0.0001 per share. While management emphasizes the notice 'has no immediate effect on the listing or trading,' extended reporting delays frequently stall SPAC merger negotiations and can precipitate trustee-led redemptions at prevailing trust values. The company identifies itself exclusively as a blank check company targeting businesses focused on 'healthcare innovation.' Chief Executive Officer and Director Junheng Xie signs the filing and states the company 'expects to regain compliance,' though management explicitly undertakes 'no obligation' to guarantee timing or outcomes. Until the FY2025 10-K is filed and Nasdaq confirms renewed compliance, shareholders face uncertainty regarding whether a completed business combination will preserve or dilute public equity value.

The extension recalibrates the public shareholder redemption window to May 6, 2026, preserving the right to exit before forced trust liquidation. The $34,330.96 trust infusion maintains per-share liquidity by covering the contractual extension cost without dipping into non-trust operating reserves. The joint payee arrangement between the Sponsor and United Hydrogen Group Inc., coupled with the note’s singular conversion and maturity trigger tied to a United Hydrogen Group Inc. transaction, indicates targeted negotiation activity rather than an open-ended search phase. The document contains no substantive disclosures regarding customers, revenue streams, market size, technology capabilities, commercial partnerships, litigation exposure, or personnel changes. The company’s stated strategic posture remains narrowly defined by the obligation to close a business combination within the newly granted calendar month, with all note provisions governed by New York law.

A late-filing notification signals audit or internal review pacing issues that typically compel SPAC sponsors to stretch the business combination timeline to avoid delisting or forced liquidation. For a searching vehicle, extending the reporting gap delays the publication of audited revenue, customer concentration, and market-size assertions that public shareholders rely on to calibrate redemption decisions.

The filing relocates the redemption deadline to April 6, 2026, preserving public trust capital while layering on a sponsor-backed credit instrument explicitly tied to a single acquisition pathway. Because the Payees irrevocably waived trust recourse, public shareholder recovery remains mathematically isolated from the extension debt. The document contains no disclosures regarding customers, revenue, market size, corporate strategy, proprietary technology, broader partnerships, ongoing litigation, or personnel changes beyond naming United Hydrogen Group Inc. as the designated business combination counterparty and identifying Junheng Xie as the executing officer. For investors tracking SPAC cadence, the sixteenth authorized extension signals advanced paper-mileage consumption without introducing new operational fundamentals or alternative merger candidates.

This document materially resets the public shareholder redemption deadline to March 6, 2026, preserving existing trust capital while buying additional months for target diligence. The sponsor-backed extension structure prevents direct trust depletion, but the fifteenth consecutive extension signals prolonged pre-combination status that typically correlates with heightened redemption risk and investor fatigue. Locking in United Hydrogen as the named counterparty removes pipeline ambiguity and allows investors to evaluate the specific merger economics once prospectus filings resume. The explicit $10.00 conversion price and trust-recourse waiver establish predictable post-transaction dilution parameters and isolate lender downside, respectively. With executive leadership unchanged, the Company maintains unified execution authority to navigate the final extension window.

Redemption calendar: The deadline shifts to February 6, 2026. As the fourteenth permitted extension, the Company is nearing its maximum allowable extension period under its charter, heightening near-term liquidation risk if no combination closes. Trust mechanics & sponsor conduct: Public shareholders receive the pro-rata extension payment, but the Company is deferring cash outlays by borrowing from its sponsor and United Hydrogen Group Inc. on a non-interest-bearing basis. Because the note’s maturity and conversion are explicitly tied to a United Hydrogen Group Inc. combination, the payees are financially aligning with the extension timeline while securing future equity upside at a fixed $10.00 conversion price. Other substance: The filing contains no independent claims regarding customer metrics, revenue projections, market sizing, technology roadmaps, strategic partnerships, or litigation status; all reported facts are confined to the extension mechanics, trust deposit calculation, note terms, and the identified counterparty for the targeted combination.

This filing directly revises the redemption calendar, establishing January 6, 2026 as the new liquidation deadline. The disclosed funding structure indicates that extension costs are serviced through sponsored debt rather than trust drawdowns, which preserves the per-share trust balance documented in earlier submissions. By attaching formal waivers against trust account recourse and linking the promissory note’s maturity exclusively to a future United Hydrogen transaction, the registrant clarifies the downside risk architecture for public shareholders while signaling sustained pursuit of that specific counterpart. Because the submission contains no executed merger agreement, valuation metrics, or shareholder voting materials, holders retain unchanged redemption entitlements up to the new deadline while monitoring subsequent deal developments.

The simultaneous approval of a two-year extension and massive share redemption drastically alters the SPAC’s capital structure and liquidity profile. Redeeming 3,942,661 Public Shares draws approximately $44.8 million from the trust, leaving approximately $0.7 million in liquidity against the December 6, 2026 termination date. The capped extension fee ($80,000 maximum versus the prior $150,000 baseline) changes the sponsor’s cash outflow schedule, though the remaining trust balance may not cover dissolution expenses or ongoing operations without further capital contributions. The linkage between the current redemption volume and the previously sanctioned United Hydrogen Business Combination indicates that 2,942,050 shareholders effectively withdrew ahead of the merger event, while 987,260 will remain invested until deal closing. The appointment of MaloneBailey, LLP shifts the external audit provider, requiring scrutiny of subsequent financial filings for compliance continuity. With only 2,179,072 shares outstanding post-extension and redemption, public float metrics and trading liquidity will contract sharply through the remainder of the 2026 search period.

The November 4 extension fixes December 6, 2025 as the final deadline before statutory liquidation, compressing the timeframe for the next investor action (proxy vote or redemption) ahead of the anticipated early 2026 merger close. The reduction of total trust capital but increase in per-share value to $11.37 highlights heavy outflows coupled with compounding interest on the remaining pool. The joint extension-funding arrangement signals target-sponsor alignment, though near-zero operating cash ($2,979), a $2,749,480 working capital deficit, and a going concern disclaimer emphasize reliance on pending transaction financing and execution risk prior to merger consummation.

This routine compliance exhibit does not alter trust valuation, adjust redemption deadlines, grant business combination extensions, or update merger progression. Chief Executive Officer and Director Junheng Xie attributed the delay solely to an incomplete internal review of the quarterly report, effectively ruling out undisclosed accounting restatements or liquidity shortfalls as causes.

This 8-K definitively locks the redemption baseline and settlement timeline, with 3,950,411 shares formally tendered against the 6,121,733 record-date pool, directly dictating trust distribution magnitude and post-combination capitalization. The explicit Extension Proxy Statement filing and December 6, 2025 deadline establish the active liquidity runway management strategy, signaling that the Company anticipates regulatory pacing could require a formal continuation vote rather than facing automatic dissolution. Tracking these mechanics is critical for evaluating whether remaining net assets will sustain Nasdaq listing requirements alongside the ~157,568,133 planned new shares. Beyond these SPAC-specific mechanics, the filing contains no material claims regarding customers, revenue, market size, corporate strategy, technology, partnerships, ongoing litigation, or senior personnel shifts beyond the execution attestation by Chief Executive Officer Junheng Xie.

FIRST, extending the deadline to December 6, 2026 prevents immediate forced liquidation and aligns the timeline with management’s stated expectation to obtain regulatory approvals and shareholder consents to close the United Hydrogen merger in early 2026. SECOND, the reduced per-extension funding mechanism lowers the sponsor’s recurring cash obligation while still injecting capital into the trust, though it alters the per-share economic trajectory compared to the prior flat fee. THIRD, the reported $11.33 per-share redemption value creates a material outflow incentive for public holders who prefer guaranteed returns over remaining invested in a SPAC facing potential delay or liquidation. FOURTH, insider ownership remains substantial at ~33.60%, though founders’ non-redeemable securities expire worthless upon liquidation, structurally aligning their incentives to close the transaction. FIFTH, no explicit claims regarding customer metrics, revenue, market size, technology, litigation, or personnel changes are disclosed, consistent with standard SPAC proxy filings focused on transaction mechanics and corporate governance.

For shareholders, the redemption and liquidation deadline is now fixed at December 6, 2025. Because this is the final permitted extension, missing this date mandates trust dissolution and per-share distribution. The $150,000 deposit provides a defined, though filing-undisclosed, incremental boost to total trust assets. The explicit linkage of the note’s maturity and the extension to United Hydrogen signals sponsor-backed target alignment. Structurally, excluding the note from trust recourse protects public shares from dilution if the SPAC fails to combine, while the optional conversion feature at $10.00 establishes a clear path for sponsor-related equity participation post-deal.

Grants the SPAC two additional years to finalize its pending merger with United Hydrogen Group Inc. (Agreement dated June 19, 2024), pushing back potential liquidation and allowing shareholders to potentially participate in the deal rather than receiving the ~$11.33 per share trust redemption value as of September 26, 2025. The reduced fee structure eases the sponsor’s funding burden, lowering the risk of missed extension payments that would force an earlier wind-up. Investors face a fixed November 24, 2025 tender deadline; failure to act locks capital into publicly traded securities subject to market volatility until the new 2026 termination threshold or closing. The audit firm rotation and adjournment authority are routine corporate governance updates.

Public shareholders must deliver shares to Continental Stock Transfer & Trust Company by November 4, 2025 to secure the ~$11.37 redemption price, but face a 15% per-investor redemption cap and a closing condition requiring at least $5,000,001 in net tangible assets post-redemption. If the November 6 vote fails or CSRC review delays past the Outside Date, the SPAC may continue depositing extension fees to preserve the trust until December 6, 2025, after which liquidation distributes pro-rata trust balances minus dissolution costs. The Sponsor’s payment of extensions and waiver of redemptions indicates sustained deal pursuit despite compressed timelines, while the dual-class governance structure ensures non-redeeming public shareholders retain economic exposure but forfeit meaningful voting influence. Execution risks highlighted by United Hydrogen’s management—including heavy customer concentration (top four customers comprised 14.6%, 14.2%, 12.7%, and 11.1% of 2024 revenues), reliance on third-party construction contractors, and unresolved CSRC oversight—directly challenge the feasibility of the projected scale-up required to justify the $10.00 per-share conversion valuation.

Strategic and operational substance: The filing demonstrates management’s reliance on sponsor-directed debt rather than independent market financing to preserve runway, structurally tying the extension capital to the proposed United Hydrogen target. The explicit trust waiver shields the trust balance from creditor claims, protecting public shareholder redemption value if the merger fails, but simultaneously eliminates recourse against those funds. Personnel authority is confirmed by Chief Executive Officer and Director Junheng Xie. The document contains no forward-looking claims regarding customers, revenue projections, market sizing, technology pipelines, or partnership valuations; it is purely a capital structure and procedural disclosure. For tracking purposes, the deposit temporarily stabilizes the trust until the November 6, 2025 deadline while introducing potential post-combination dilution through the voluntary unit conversion feature, clarifying that sponsor contributions remain contractually subordinate to public trust distributions.

The filing pushes back any mandatory redemption or liquidation deadline to October 6, 2025, keeping the SPAC in 'SEARCHING' status for another month. Public shareholders see $150,000 leave their trust balance to fund the extension while the Company incurs a $150,000 liability. As disclosed in Exhibit 10.1, Payees explicitly waive all rights to the trust account, meaning default repayment would fall on non-trust assets. The note grants Payees a non-obligatory conversion right into private units at $10.00 per unit (each consisting of one ordinary share and a right to one-fifth of one ordinary share) if exercised with at least two business days' written notice prior to closing, introducing potential dilution mechanics ahead of a target deal. Executed by Chief Executive Officer and Director Junheng Xie, the disclosure confirms the Sponsor and United Hydrogen are co-funding the extension while signaling the Company’s continued pursuit of a combination with United Hydrogen.

An SEC comment letter that forces a comprehensive amendment specifically to add PRC risk disclosure is a signal about the transaction's substance: the regulator saw China-related exposure material enough to require restated risk factors before the deal could proceed. For a holder weighing whether to redeem or stay through the United Hydrogen combination, PRC regulatory, HFCAA and variable-interest-entity risks now sit in the annual report rather than being absent from it. No financial figures were changed.

The significant reduction in redeemable shares mechanically increased the per-share trust value to $11.14, raising the potential redemption payout for remaining public shareholders relative to the initial trust allocation. The shift to a flat $150,000 monthly extension fee applies to the reduced share count, concentrating the extension cost per remaining holder, though the obligation is shared with United Hydrogen through issued promissory notes rather than requiring immediate cash outlays from the operating entity. Management explicitly states in the Going Concern Consideration section that the inability to complete a business combination by September 6, 2025 raises substantial doubt about the Company’s ability to continue as a going concern, directly tying the September 6, 2025 deadline to existential liquidity risk. The Company’s external operating cash stands at $2,138 with a working capital deficit of $2,169,328, indicating heavy reliance on Trust Account interest ($1,064,650 earned over six months) and sponsor/target-funded extension notes to sustain corporate existence through the deadline.

The extension delays any mandatory redemption consideration or trust liquidation event until September 6, 2025, confirming continued pursuit of United Hydrogen Group Inc. as the acquisition target. The sponsor-backed financing and trust waiver remove repayment pressure from the trust but concentrate liquidity risk on the Company’s non-trust corporate assets. The conversion provision at $10.00 per unit establishes specific dilution mechanics for private equity allocation at closing. Section 5 of the promissory note establishes clear default triggers, including failure to pay principal more than 5 business days past maturity, voluntary or involuntary bankruptcy filings, or material breaches, granting immediate acceleration rights to lenders. The prolonged extension timeline, now at nine of twelve allowed, signals extended deal execution without introducing new commercial, technological, customer, or strategic disclosures beyond the named counterparty.

What changed: This is a Form 8-K Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically disclosing the termination of a material definitive agreement and furnishing a press release under Regulation FD. Effective July 7, 2026, the Company delivered a notice of termination to United Hydrogen Group Inc. and four affiliated Cayman Islands entities, permanently ending the Business Combination Agreement originally dated June 19, 2024, and amended June 6, 2025. Per Section 9.1(b) of the contract, the termination was triggered solely by the lapse of the applicable outside date without consummation of the closing. This action immediately halts any pending redemption calendar, shareholder approval meeting, or proxy solicitation previously tied to the United Hydrogen merger. The filing does not revise the trust account distribution amount, set a new redemption deadline, or formally authorize a timeline extension. Why it matters: The termination collapses the current merger pathway, reverting the SPAC to a searching posture and suspending any outstanding redemption windows until management identifies a replacement target or triggers charter dissolution. In the attached press release, Chief Executive Officer and Director Xie Junheng stated that although the company failed to complete the proposed combination within the required timeframe, the leadership team remains confident in its ability to identify and execute a compelling transaction in the future, and he publicly thanked the United Hydrogen team for their efforts and professionalism. The document contains no operating data, customer lists, revenue figures, market size estimates, proprietary technology descriptions, or ongoing partnership details. Junheng Xie executed the report in his capacity as Principal Executive Officer, providing the corporate mailing address at 10 East 53rd Street, Suite 3001, New York, NY 10022, and the contact email Xiejunheng@aimeihealth.com. Investors monitoring redemption deadlines and trust value should treat this as a terminal event for the current deal track and await supplemental filings that will clarify whether the board will seek an extension amendment, pursue a new business combination, or initiate mandatory liquidation distributions per the existing charter.

What changed: SEC Form 8-K Current Report (Items 2.03 and 9.01) disclosing the extension of the SPAC termination date and the issuance of a sponsor-backed promissory note to fund the monthly extension fee. According to the company's 8-K filing, the deadline to complete an initial business combination has been extended by one month, moving the Termination Date from July 6, 2026 to August 6, 2026. The filing states this constitutes the twentieth extension permitted under the Amended and Restated Articles of Association. Per the registrant's disclosure, an aggregate of $34,330.96 was deposited into the trust account for public shareholders, which the text describes as representing “the lessor of (i) $80,000 for all outstanding public shares and (ii) $0.033 for each outstanding public share for each monthly extension.” To finance this deposit, the company issued a $34,330.96 unsecured promissory note to Aimei Health Ltd. The note bears zero interest, becomes due solely upon business combination consummation, and grants the holder the unilateral right to convert the principal into private units at $10.00 per unit (each unit comprising one ordinary share and a right to one-fifth of an ordinary share) provided written notice is delivered at least two business days before closing. The payee contractually waived all rights and claims against the trust account funds. Junheng Xie, Chief Executive Officer and Director, signed the report attesting to these terms on the registrant’s behalf. Why it matters: Beyond the calendar adjustment, the filing identifies United Hydrogen Group Inc. as the designated target for the planned Business Combination, offering concrete progress on deal execution while deferring the mandatory redemption/liquidation trigger until the new August 6, 2026 milestone. Sponsor conduct demonstrates continued financial support through a convertible debt instrument rather than immediate cash infusion or secondary offerings, though election of the conversion option would increase post-combination share count at the fixed $10.00 per unit conversion rate. The document contains no claims regarding customer acquisitions, revenue milestones, market size projections, proprietary technology, or active litigation, nor does it disclose executive departures or board realignments. Because the extension payment was routed through the promissory note directly into trust, operating liquidity remains untouched, and the filing triggers no new shareholder vote requirements or redemption pricing recalculations. Investors awaiting the liquidation timeline should monitor whether the sponsor exercises the conversion right prior to the August 6, 2026 cutoff or advances the transaction to avoid further extension cycles.

What changed: SEC Form 3 insider ownership report. According to the filing, there are 'No non-derivative transactions or holdings reported' for reporting person Polvi Daniel Veikko (director). This routine compliance exhibit registers zero changes to insider equity positions. Why it matters: As a standard regulatory snapshot of initial or unadjusted beneficial ownership, the filing moves neither the redemption deadline, the trust account balance, nor the extension timeline. It offers no signal regarding sponsor alignment, underwriter commitments, or the pace of due diligence toward a definitive merger agreement. Because the submission records no equity activity, it contains no data on customer pipelines, revenue run rates, technology milestones, partnership structures, or litigation exposure for Aimei Health Technology Co., Ltd.

What changed: This document is a Form 8-K current report disclosing Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers) and Item 9.01 (Exhibits). This document is a Form 8-K current report. Regarding redemption deadlines, trust value, extensions, deal progress, and sponsor conduct, the filing introduces no modifications to those mechanics. The SPAC’s trust account arrangements, shareholder redemption window, and extension provisions remain unchanged, and the registrant continues to operate without a disclosed business combination target or sponsor activity update. Regarding personnel and other substance, Ms. Julianne Huh submitted a letter of resignation as a director effective June 24, 2026, which the Board accepted. Ms. Huh advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. She acknowledged that she has been paid all amounts due to her and irrevocably released the Company from claims. On June 29, 2026, the nominating and corporate governance committee recommended, and the Board approved and appointed Mr. Daniel Veikko Polvi as a director. Mr. Polvi received an MBA degree in Business Administration from BI Norwegian Business School in June 2018. Since May 2019, Mr. Polvi has served as managing director of Shearwater Limited. The Board believes Mr. Polvi is well qualified due to his extensive experience in business management, corporate advisory, and strategic consulting for international corporations. The Company confirmed there are no family relationships between Mr. Polvi and any director or executive officer of the Company, and no disclosable transactions under Item 404(a). Chief Executive Officer and Director Junheng Xie signed the filing on June 29, 2026. Why it matters: For investors tracking redemption calendars, trust distributions, and deal progression, this filing confirms that AFJK remains in a pre-combination searching phase with no alterations to the existing liquidation mechanics, redemption eligibility dates, or extension provisions. The director transition reflects standard post-IPO governance rotation rather than transaction-execution restructuring. Because the filing contains no announcements regarding a merger partner, purchase price, lock-up terms, or sponsor funding commitments, it provides no concrete signal regarding upcoming shareholder votes or deal closing timelines. The appointment of an independent management consultant to the board may indicate preparatory oversight capacity, but absent a target declaration, shareholder liquidity remains governed by the original prospectus framework. All statements regarding Ms. Huh’s departure rationale and Mr. Polvi’s professional background were attributed to the Company or its Board.

What changed: Form 10-Q Quarterly Report. According to the filing, the trust account balance rose to $12,276,196 (approximately $11.80 per redeemable share) from $12,100,110 at December 31, 2025, driven by interest earnings. Management states the SPAC extended its combination deadline through July 6, 2026 by securing monthly extension loans funded by the Sponsor and United Hydrogen ($34,331 each for the quarter). The filing notes the administrative services agreement with the Sponsor expired on December 31, 2025, after which the Sponsor began providing office space free of charge. Regarding the proposed United Hydrogen merger, management reports that Chinese regulatory approvals remain pending following a CSRC review initiated on August 12, 2024, and management expects the transaction to close in late 2026. Why it matters: The extension funding and updated deadline confirm continued sponsor and partner commitment, signaling that shareholder capital will remain locked up until mid-to-late 2026 and preserving the option to redeem. The rising trust value provides downside protection above the original deposit level. However, the explicit acknowledgment of prolonged CSRC review cycles highlights sustained regulatory execution risk, meaning public shareholders must decide whether to hold, wait for late-2026 developments, or exercise redemption rights before the newly set summer deadline.

What changed: Form 8-K Current Report (Items 2.03 and 9.01) reporting the creation of a direct financial obligation via a promissory note to fund a single-month extension of the SPAC’s business combination deadline. As described in the filing itself, this document discloses a funded extension mechanism paired with a corresponding sponsor liability. Per the registrant’s disclosures, $34,330.96 was deposited into the trust account to extend the termination date from June 6, 2026 to July 6, 2026, marking the nineteenth authorized extension under the Amended and Restated Articles of Association. The Company financed the deposit by issuing a $34,330.96 unsecured promissory note on June 4, 2026, payable to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc., with each payee allocated exactly $17,165.48. The note bears zero interest, matures solely upon the closing of a business combination with United Hydrogen, and grants the Payees the optional right to convert it into private units at a fixed $10.00 per unit price (comprising one ordinary share and a right to receive one-fifth of one ordinary share), contingent on written notice delivered at least two business days prior to closing. The Payees expressly waived all rights and claims to the Trust Account Funds, stipulating that if the Company does not consummate a business combination, the note will only be repaid from non-trust sources. The filing was executed by Chief Executive Officer and Director Junheng Xie, and explicitly identifies United Hydrogen Group Inc. as the Company’s targeted merger counterpart, concluding the earlier indefinite search phase. Why it matters: Public shareholders tracking the redemption calendar must now align their exercise windows to the revised July 6, 2026 liquidation trigger, preserving their statutory right to redeem shares at the prevailing trust value before that date. By routing the extension funding through a sponsor-led promissory note that contractually surrenders recourse to the trust account, the Company structurally protects existing public trust balances from external creditor claims while securing additional operational runway. The explicit inclusion of United Hydrogen Group Inc. as a co-payee on the extension debt provides verified, contract-level evidence of deal negotiation progression, materially reducing information asymmetry regarding target selection. The predetermined $10.00 conversion floor locks in the exact post-combination unit economics for participating sponsors, establishing clear dilution parameters ahead of a definitive proxy statement or merger agreement.

What changed: A Form 8-K Current Report containing Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) and Item 9.01 (Exhibits), accompanied by Exhibit 99.1, a press release regarding a Nasdaq listing deficiency notice. On May 19, 2026, the Company disclosed receipt of a Nasdaq listing deficiency notice stating it violated Nasdaq Listing Rule 5250(c)(1) for failing to file its Form 10-Q for the period ended March 31, 2026 by the May 15, 2026 deadline. The Company noted it has 60 calendar days from the notice date to file the report or submit a compliance plan, and could receive up to 180 calendar days from the report’s due date if Nasdaq accepts the plan. Why it matters: The notice establishes a clear delisting pathway should the Company miss its filing window or fail to satisfy Nasdaq’s conditions. For a SPAC awaiting a merger closure, an administrative lag and potential exchange removal risk can pressure shareholder sentiment around redemption timing. Management stated it expects to regain compliance and reiterated its strategic focus on healthcare innovation. Because the filing provides no updated financials, investors cannot track interim trust balance consumption or sponsorship funding milestones during the 60-day or 180-day cure periods, leaving standard redemption deadline mechanics unchanged but operationally opaque.

What changed: An SEC Form 8-K Current Report filed by Aimei Health Technology Co., Ltd. functioning as a routine compliance exhibit that discloses a monthly deadline extension and the concurrent issuance of a promissory note. The registrant reports depositing an aggregate $34,330.96 into the trust account, which the filing describes as representing the lessor of (i) $80,000 for all outstanding public shares and (ii) $0.033 for each outstanding public share for each monthly extension. According to the Company, this payment extends the Termination Date from May 6, 2026 to June 6, 2026, constituting the eighteenth extension permitted under the Amended and Restated Articles of Association. The filing discloses that the Company issued an unsecured promissory note for $34,330.96 to Aimei Health Ltd (identified as the Sponsor) and United Hydrogen Group Inc. Per the exhibit, each Payee contributed exactly $17,165.48 to fund the extension payment. The note states it accrues no interest and the principal becomes payable only upon consummating a business combination with United Hydrogen. The attachment further details that the Payees hold a non-binding conversion right to exchange the note for private units at $10.00 per unit, contingent on delivering written notice at least two business days before closing. Chief Executive Officer and Director Junheng Xie signed the filing. Why it matters: Because the registrant advanced the Termination Date to June 6, 2026, public shareholders retain an additional thirty-day redemption window prior to the next extension cycle. The $34,330.96 deposit mechanically increases the trust balance allocated to satisfy potential redemptions. The filing reveals that the Sponsor and United Hydrogen Group Inc. are funding the extension period through a deferred credit instrument rather than immediate equity; the $34,330.96 obligation carries zero interest and will either convert to equity post-merger or mature at the closing date. As the Company identifies this as the eighteenth allowable extension, it indicates the SPAC is operating near the statutory extension ceiling, extending execution uncertainty. Under Sections 8 and 12 of the Promissory Note, the Payees expressly waive all claims against the trust account, legally ring-fencing those deposited funds exclusively for public shareholders in the event of liquidation. The submission contains no disclosures regarding projected revenues, target customer bases, market sizing, proprietary technology, strategic partnerships, pending litigation, or executive compensation changes.

What changed: Form 10-K annual report for the fiscal year ended December 31, 2025. The registrant reports that the Trust Account balance fell to $12,100,110 after $65,326,328 in shares were redeemed. Management extended the business combination deadline to May 6, 2026, lowering the monthly extension deposits to $34,330.96. The company notes that shareholder approval for the United Hydrogen merger was obtained on November 6, 2025, but Chinese CSRC approval remains pending, with a targeted closing in May 2026. Additionally, management identified a material weakness in internal controls over financial reporting stemming from inadequate segregation of duties. Why it matters: The scale of redemptions indicates strong capital flight, directly reducing the pool available for either a completed merger or pro-rata liquidation distributions. The delayed timeline and ongoing regulatory hurdles shift market and liquidity risk well into 2026, while the disclosed internal control deficiency introduces potential audit and restatement risks that could further complicate the transaction or trigger a liquidation event.